Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss

Korábbi kezelés

• Currently using non-GLP-1 RA medications for weight-loss, or have undergone or plan to undergo weight-loss procedures within the next 4 months;

Más betegség

• Be allergic or intolerance to inulin-type substances;

Egyéb

• Long-term user of prebiotics or probiotics (excluding fermented dairy products such as yogurt);
• Have participated in in other clinical trials within the past 3 months or are currently participating in other clinical trials;
• Plan to be pregnant within the next year, are currently pregnant, or are breastfeeding;
• Deemed unsuitable for participation by the investigator's judgment.

• Be overweight or obese (meeting any of the following criteria):
  • Obesity: BMI >=28 kg/m²;
  • Overweight (BMI >= 24 kg/m²) with at least one body weight-related comorbidity: obstructive sleep apnea syndrome, prediabetes, type 2 diabetes mellitus, hypertension, dyslipidemia, polycystic ovary syndrome, or non-alcoholic fatty liver disease.
• Must have received GLP-1 RA drugs (Semaglutide, Liraglutide, Benaglutide, Tirzepatide, or Mazdutide) for weight-loss intervention for at least 3 months, and plan to continue using them for the next six months.
• Age 18-64 years.
• Consent to participate and sign the informed consent form.